9 results about "Chronic infection" patented technology

Helicobacter pylori (HP) is a chronic bacterium that infects the gastric mucosa. It is widespread in the general population, with an infection rate between 55% and 70%. HP is closely related to gastric ulcers and gastritis. Western medicine treatment for HP infection is relatively complex, including bismuth substituents and proton pump inhibitors plus two antibiotics. Gastric ulcers and gastritis are common digestive system diseases. Compound 1, "Exterminate the Ghost," is a traditional Chinese medicine composition mainly composed of Coptis chinensis, plus Scutellaria baicalensis and Fraxinus chinensis, which can eradicate HP. Compound 2, "Ulcer Relief," is a traditional Chinese medicine composition mainly composed of Coptis chinensis, plus Rheum palmatum and Bletilla striata, which can cure gastric ulcers. Compound 3, "Gasitis Relief," is a traditional Chinese medicine composition mainly composed of Coptis chinensis, plus Glycyrrhiza uralensis or Taraxacum mongolicum, made into a tea bag, which can cure chronic gastritis.

The application discloses an N-(3-cyclobutyrolactone)-4-nitrophenyl butyryl amide and amikacin composition and application of the composition in treating chronic infection of drug-resistant bacteria. After the N-(3-cyclobutyrolactone)-4-nitrophenyl butyryl amide and the amikacin are combined, not only the sensitivity of pseudomonas aeruginosa to the amikacin can be obviously increased, but also the formation amount of the pseudomonas aeruginosa biofilm can be greatly reduced, so that the composition can be applied to preventing and treating chronic infection of drug-resistant pseudomonas aeruginosa.

This invention discloses the construction of a Toxoplasma gondii progesterone-responsive kinase-deficient strain and its application as a live attenuated vaccine. The Toxoplasma gondii progesterone-responsive kinase-deficient strain is derived from Toxoplasma gondii RHΔ... ku80 As a maternal strain, the gene-editing technology was used to knock out the enzyme encoding progesterone-responsive kinase. prk The gene-deleted strain was named RHΔ ku80 Δ prk Experiments have shown that RHΔ ku80 Δ prk The virulence of the strain was significantly reduced, and immunized mice showed good immunoprotection against acute infection with highly virulent and moderately virulent Toxoplasma gondii strains, and significantly inhibited brain cyst formation in a chronic infection model. Therefore, RHΔ ku80 Δ prk This invention has potential application value as a live attenuated vaccine against Toxoplasma gondii. It has significant application prospects.

The application discloses a method for constructing an animal model of chronic pulmonary infection / persistence of Acinetobacter baumannii, and belongs to the technical field of infectious disease animal model construction and microbial preparation. Compared with the acute infection and rapid clearance mode formed by directly inoculating free bacteria, the live bacterial microspheres prepared in the application can prolong the local exposure and detectable time of Acinetobacter baumannii in the lung, so that the Acinetobacter baumannii is more likely to form a low-load, long-term persistence pulmonary infection state, thereby providing a more stable experimental platform for the mechanism of chronic infection formation, host immune dynamic change and related intervention evaluation.

This invention relates to a fusion antigen mRNA molecule, which encodes a protein comprising at least two of the following: hepatitis B surface antigen protein sHBsAg, hepatitis B core antigen protein Core, hepatitis B X antigen protein HBxAg, and hepatitis B preS1 antigen protein PreS1, preferably comprising hepatitis B surface antigen protein sHBsAg, hepatitis B core antigen protein, and hepatitis B PreS1 antigen protein, denoted as sHBsAg-Core-PreS1, and its amino acid sequence is shown in SEQ ID No. 17; the above-mentioned fusion antigen mRNA molecule can be prepared into an mRNA-LNP vaccine composition and used to treat chronic hepatitis B virus infection. The preferred sHBsAg-Core-PreS1 mRNA-LNP of this invention can normally express and present each encoded target antigen in vivo, and achieve cross-presentation, cross-activation and enhanced expression, inducing target antigen-specific humoral and cellular immune responses. It can also effectively overcome immune tolerance in a mouse model of chronic hepatitis B, and has excellent antiviral and immunotherapeutic effects. Compared with existing related therapeutic HBV mRNA-LNP vaccines, it effectively improves the immune tolerance breakthrough threshold, providing a candidate vaccine and a new immunotherapy strategy for the immunotherapy of patients with chronic HBV infection.

The embodiments of the present application provide a method for establishing in vitro CD8 + T cell exhaustion model and application thereof. The method comprises: using T cell receptor signal stimulator combined with interleukin-10 to continuously stimulate CD8 + T cells under in vitro culture conditions. The cells induced by the method not only highly express exhaustion key transcription factor TOX and various surface inhibitory receptors (such as PD1, TIM3, LAG3 and the like), but also significantly reduce the secretion ability of effector cytokines, highly reduce the real exhaustion performance in in vivo chronic infection or tumor microenvironment in vitro, and effectively overcome the defect of few CD8 + T cells in traditional in vivo animal model, and high-quality exhaustion cells can be obtained in vitro in large scale in only 6 to 8 days.

The application discloses an intelligent responsive composite hydrogel dressing and a preparation method and application thereof, and belongs to the field of biomedical materials. The preparation method comprises the following steps: preparing arginine grafted quaternary ammonium chitosan LQ; preparing phenylboronic acid functionalized oxidized sodium alginate P-OSA; preparing a multifunctional nanoenzyme complex PMZG; mixing polyvinyl alcohol, LQ, honeysuckle extract and / or PMZG, and then cross-linking with a P-OSA solution to obtain a hydrogel. Through progressive modular design, the hydrogel is endowed with injectability, self-healing, multiple microenvironment responsiveness and cascade catalytic antibacterial, photothermal therapy and pro-angiogenesis capabilities, and can be used for synergistically treating chronic infected wounds, diabetic foot ulcers and drug-resistant bacterial infection wounds, and has a wide clinical application prospect.

OF THE INVENTION SEROLOGICAL MARKER FOR THE LATENT FORM OF TOXOPLASMOSIS In the present invention, inventors screened the bradyzoite proteome for immunogenic protein candidates in an unbiased manner and identified the Bradyzoite Serological Marker (BSM) as a second serological biomarker for Toxoplasma chronicity in mice. BSM serology correctly distinguishes cyst-bearing mice with a sensitivity and specificity of 97.96% (IC95: 89.31 - 99.90) and 100.0% (IC95: 86.20 - 100.0) respectively. In humans, both bradyzoite markers BCLA and BSM are in moderate agreement (kappa=0.308) and BSM serology is unexpectedly positive in 30% of patients with past immunity, raising many questions. Nevertheless, bradyzoite serology could provide new reference standards for studying the pathophysiology of chronic toxoplasmosis in humans, especially cyst carriage, which has been poorly described. Thus the invention relates to a new Toxoplasma gondii protein, hereafter referred as BSM, a new serological marker whose expression is restricted to the latent form of Toxoplasmosis (bradyzoite / cyst).

This invention relates to enhancing antisense oligonucleotides that are complementary to distal upstream element-binding protein 1 (FUBP1) and capable of reducing FUBP1 target nucleic acids, such as FUBP1 mRNA. This invention relates to enhancing antisense oligonucleotides or conjugates thereof targeting FUBP1 for the treatment and / or prevention of hepatitis B virus (HBV) infection, particularly chronic HBV infection. This invention particularly relates to the use of said enhancing antisense oligonucleotides or conjugates thereof targeting FUBP1 for destabilizing cccDNA, such as HBV cccDNA. This invention further relates to enhancing antisense oligonucleotides or conjugates thereof targeting FUBP1 for the treatment of cancer. This invention also includes a pharmaceutical composition and its use in the treatment and / or prevention of HBV infection, or its use in the treatment of cancer.